This week, Congress is expected to consider a USMCA trade agreement that does NOT include stronger IP protections for American innovators who develop biologic medicines. While the removal of these provisions is being hailed as a defeat for Big Pharma, here are three key points to keep in mind as…

By 2040, experts say the number of yearly cancer cases in Africa will double. In 2018 alone, cancer deaths in Africa (over 530,000) were 30 percent higher than deaths from malaria. Clearly, a shift in disease burdens has taken place on the continent. Biotechnology and pharmaceutical companies are…

In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for Politico Pulse note: “The agency [Centers for Medicare & Medicaid Services] on Friday announced a $9 monthly premium increase and $13 annual deductible hike, but argued that the White House is working to bring…

Supporters of Speaker Pelosi’s extreme drug pricing bill (H.R. 3) want us to believe that they can destroy the biopharmaceutical industry and still produce new cures and treatments for patients in need. The crux of this fairy tale is the promise by supporters of H.R. 3 to reinvest “savings” from…

Supporters of Speaker Pelosi’s drug pricing plan (H.R. 3) claim the bill will discourage the development of so-called “me too” drugs. For example, Rep. Donna Shalala was recently quoted as saying:  “I think it actually will reduce me-too drugs … I think [pharmaceutical companies] are going to…

Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event…

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones. “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates…

On Tuesday morning at the BIO Investor Forum, leaders from top companies at the forefront of gene therapy innovation assembled to discuss successful approaches, challenges in protein delivery, and the future of expanding this class of medicines. Gene therapies have the potential to increase the…

On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away. Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed…

On Tuesday, October 8, BIO formally announced that its President and CEO Jim Greenwood would be stepping down from the world's largest biotechnology organization in January 2021. In a letter to BIO staff, Greenwood reflected on his rise to BIO and the accomplishments the organization has achieved…